Bing

At Stock Options Channel, our YieldBoost formula has looked up and down the AMRN options chain for the new November 20th contracts and identified one put and one call contract of particular interest. The put …
The Street · 8/27/2015
Options Trading
Biotech stock Amarin Corporation plc (ADR) (NASDAQ:AMRN) has been quite the conversation piece lately, and for good reason. Following a major analyst upgrade from HC Wainwright a couple weeks ago, we saw tremendous gains in Amarin stock
Investor Place · 3/23/2015
I believe the stock has significant upside potential. http://seekingalpha.com/article/2586135-amarins-value-with-or-without-reduce-it... I have been hearing that there could be a huge IR campaign taking off for AMRN in the near future. I have been holding ...
Stockhouse · 8/24/2015
More from Bing News
Amarin Corporation plc (AMRN) shares are up more than 14% to $2.72 in early trading. The move comes on a big volume too with the issue currently trading more than 13.6 million shares, compared to the average volume of 4.4 million shares. The stock
Wall Street Pit · 3/18/2015
Amarin Corporation (NASDAQ:AMRN) is having a great day in the market today after a big ruling from a United States District Court in a conflict between the company and the FDA. Today, we’ll discuss what that ruling is, how it’s affecting the stock ...
investing.com · 8/9/2015
Amarin Co. plc (NASDAQ:AMRN) was downgraded by Zacks from a “hold” rating to a “sell” rating in a research report issued on Thursday, MarketBeat reports. According to Zacks, “Amarin Corporation plc is a global pharmaceutical group which …
wkrb13.com · 8/22/2015
Still, no sign of new chemical entity (NCE) status by FDA; no partnership or buyout has materialized; and the stock is hovering near pre-clinical trial result levels. However, before being too short-sided, let's quickly review some of AMRN's strengths from ...
Seeking Alpha · 3/6/2013
Amarin Corporation plc (AMRN - Snapshot Report) was a big mover last session ... This breaks the recent trend of the company as the stock is now trading above the volatile price range of $1.85–$2.07 in the past one-month time frame.
ZACKS · 5/29/2015
One stock that might be an intriguing choice for investors right now is Amarin Corporation plc (AMRN). This is because this security in the medical space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry ...
Yahoo Finance · 9/3/2014
Amarin Co. plc (NASDAQ:AMRN)‘s stock had its “market perform” rating reissued by research analysts at Oppenheimer in a note issued to investors on Tuesday, Analyst Ratings Net reports. Shares of Amarin Co. plc (NASDAQ:AMRN) opened at 2.32 …
sleekmoney.com · 8/13/2015

Amarin Corporation

Company
Amarin Corporation is a biopharmaceutical company headquartered in Bedminster, New Jersey. The company develops and markets me…
Amarin Corporation is a biopharmaceutical company headquartered in Bedminster, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. Amarin develops the drug Vascepa which is a prescription grade omega-3 fatty acid. In December 2007, the company acquired Ester Neurosciences Limited for 8.1 million USD. Amarin CEO Joe Zakrzewski has said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States. Recently on July 26, 2012, their lead-candidate drug named Vascepa received FDA-approval. Vascepa will also be a key competitor against GlaxoSmithKline's Lovaza.
Data from: Wikipedia